5-Year Outcomes After Left Atrial Appendage Closure From the PREVAIL and PROTECT AF Trials

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F12%3A00007391" target="_blank" >RIV/00023884:_____/12:00007391 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jacc.2017.10.021" target="_blank" >http://dx.doi.org/10.1016/j.jacc.2017.10.021</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jacc.2017.10.021" target="_blank" >10.1016/j.jacc.2017.10.021</a>

Jazyk výsledku

angličtina

Název v původním jazyce

5-Year Outcomes After Left Atrial Appendage Closure From the PREVAIL and PROTECT AF Trials

Popis výsledku v původním jazyce

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, St. Paul, Minnesota) was equivalent to warfarin for preventing stroke in atrial fibrillation, but had a high rate of complications. In a second randomized trial, PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy), the complication rate was low. The warfarin cohort experienced an unexpectedly low ischemic stroke rate, rendering the efficacy endpoints inconclusive. However, these outcomes were based on relatively few patients followed for a relatively short time.

Název v anglickém jazyce

5-Year Outcomes After Left Atrial Appendage Closure From the PREVAIL and PROTECT AF Trials

Popis výsledku anglicky

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, St. Paul, Minnesota) was equivalent to warfarin for preventing stroke in atrial fibrillation, but had a high rate of complications. In a second randomized trial, PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy), the complication rate was low. The warfarin cohort experienced an unexpectedly low ischemic stroke rate, rendering the efficacy endpoints inconclusive. However, these outcomes were based on relatively few patients followed for a relatively short time.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the American College of Cardiology

ISSN

0735-1097

e-ISSN

—

Svazek periodika

70

Číslo periodika v rámci svazku

24

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

2964-2975

Kód UT WoS článku

000418262500003

EID výsledku v databázi Scopus

2-s2.0-85035008707